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Cardiac electrophysiologic derangements often coexist with disorders of the circulatory
system. Capturing and diagnosing arrhythmias and conduction system disease may lead
to a change in diagnosis, clinical management and patient outcomes. Standard 12-lead
electrocardiogram (ECG), Holter monitors and event recorders have served as useful
diagnostic tools over the last few decades. However, their shortcomings are only recently
being addressed by emerging technologies. With advances in device miniaturization and
wireless technologies, and changing consumer expectations, wearable “on-body” ECG
patch devices have evolved to meet contemporary needs. These devices are unobtrusive
and easy to use, leading to increased device wear time and diagnostic yield. While
becoming the standard for detecting arrhythmias and conduction system disorders in
the outpatient setting where continuous ECG monitoring in the short to medium term
(days to weeks) is indicated, these cardiac devices and related digital mobile health
technologies are reshaping the clinician-patient interface with important implications for
future healthcare delivery.
Keywords: electrocardiography, medical devices, arrhythmias, cardiac, conduction system disorders, ambulatory
patients, healthcare delivery
Introduction
Sustained and intermittent atrial and ventricular arrhythmias, conduction system disease,
and abnormally high ectopic burden can be important markers of cardiovascular disease
in the appropriate clinical settings. Their presence may also reflect underlying myocardial
ischemia, inflammation, cardiac fibrosis, myocardial tissue inhomogeneity, and/or mechanical
stress from deranged hemodynamics. An inappropriately high burden of ventricular premature
complexes (>20,000 per day) and frequent tachyarrhythmias may result, over time, in
left ventricular dysfunction and heart failure due to tachycardia-mediated cardiomyopathy
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(Shinbane et al., 1997; Duffee et al., 1998; Takemoto et al.,
2005). Atrial arrhythmias such as atrial fibrillation (AF) and atrial
flutter (AFL) are prothrombotic (Gallagher et al., 1997; Zipes,
1997; Sparks et al., 1999; Stoddard, 2000; Thambidorai et al.,
2005; Alyeshmerni et al., 2013), predisposing to cardioembolic
stroke (Wolf et al., 1978; Biblo et al., 2001; Halligan et al.,
2004; Parikh et al., 2012). Importantly, accumulating evidence
supports a link between AF and sudden cardiac death as well
as increased mortality and rehospitalization related to congestive
heart failure (Mentz et al., 2012; Chen et al., 2013; Reinier
et al., 2014). Sustained or intermittent bradyarrhythmias can
also lead to functional limitations in activity, lightheadedness,
near syncope and syncope, can limit or contraindicate the
use of medications for heart failure or arrhythmias, and can
predispose to pause-dependent tachyarrhythmias such as torsade
de pointes. Thus, early detection of, and prompt intervention on,
suspect arrhythmias may prevent the subsequent development
of worsening functional class and devastating complications
including cardiomyopathy, heart failure, stroke and sudden
cardiac death. In cardiomyopathy and heart failure, detection
and control of arrhythmia can result in reversal of pathologic
remodeling. Conventional and recently developed non-invasive
ambulatory electrocardiographic (AECG) monitors can be useful
for revealing previously undiagnosed arrhythmias of significance
and may alter the course of clinical management.
The term “cardiac arrhythmia” encompasses a spectrum of
rhythm disturbances that may or may not be symptomatic.
Symptoms such as palpitations, lightheadedness and syncope
are important indications for performing AECG. Furthermore,
cardiac studies such as echocardiography showing atrial and
ventricular tachy- or bradyarrhythmias and ECG findings of
conduction pathway anomalies, would also prompt a period of
continuous ECG monitoring in order to investigate temporal
variations, overall burden, and to enhance diagnosis. A 12-
lead ECG provides a detailed, calibrated snapshot of heart
rate, rhythm, conduction, and repolarization from multiple
lead vectors within a 10-second time frame. Pathophysiologic
states including current or pre-existing ischemia, infarction,
left ventricular hypertrophy, and heritable arrhythmic disorders
may also be revealed. But it is often insufficient for ruling out
intermittent arrhythmias especially in the outpatient setting.
The strength of a 12-lead ECG is the ability to assess rhythm,
conduction, repolarization from multiple lead vectors allowing
diagnosis of cardiac structural, electrophysiologic, and metabolic
abnormalities and drug effects, but it is limited by the duration of
rhythm detection. The choice and study duration of continuous
ECG monitoring (Figure 1) is guided by the clinical questions to
be answered from clinical history and physical examination.With
increasing availability of ECGmonitoring as consumer products,
patients’ preferences may also dictate the duration and mode of
monitoring required and, in turn, the selection of device to use.
In general, for a shorter study period (e.g., days vs. weeks to
months) placement of a device that is relatively less invasive at
the time of deployment (e.g., wearable monitor vs. implantable
loop recorder) is preferable.
In documenting and reporting arrhythmic events, the
term “episode” is used to describe onset of a self-limiting
bout of arrhythmia and an episode count can be useful
for paroxysmal arrhythmic events or salvos; however, the
descriptor lacks a temporal dimension and does not incorporate
frequency and duration of the arrhythmia. “Arrhythmia burden”
can be defined as the percentage of time in arrhythmia
over the total interval of recording (Euler and Friedman,
2003). This definition has been accepted as the standard for
quantifying the overall frequency or extent of arrhythmic
episodes, and serves also as a durable surrogate endpoint
for clinical outcomes in demonstrating biologic effects of a
therapy on the target arrhythmia (Euler and Friedman, 2003).
For instance, successful suppression of arrhythmia by an
antiarrhythmic drug should result in a reduction in arrhythmia
burden.
This review summarizes not only the options and
contemporary use of AECG and related devices but also
highlights the changing consumer access to increasingly
ubiquitous mobile medical devices, consumers’ growing
involvement in self-care and diagnosis, and the implications for
personal controlled health records (PCHR).
Trends in Ambulatory ECG and Rhythm
Monitoring Systems
In recent years, innovative engineering and advances in
manufacturing have hastened the development of miniaturized
medical devices, and yielded a variety of cardiac monitors
for ambulatory use. These recently developed wearable, “on-
body” ambulatory devices have integrated microelectronics (e.g.,
ZIO R© XT Patch, NUVANT R© or SEEQ R© MCT; see below) for
short to medium term (days to weeks) monitoring, and are
challenging conventional, widely used devices from the last
decades that were limited to wearable multi-lead 24-/48-h Holter
monitors and event recorders (Figure 1 and Table 1). Further
on the pioneering front, very short-term (seconds to minutes)
handheld smartphone-enabled systems (e.g., AliveCor R©, ECG
Check) (Figure 2) are beginning to reshape the field of mobile
cardiac monitors as well as the clinician-patient interface. These
systems require attachment of an electrode-embedded module
to a smartphone that detects electrical impulses from the user’s
fingertips and transmits signals to the mobile device to generate
continuous single-channel ECG for the duration of the contact
between the fingers and the sensor. While the open commercial
availability of these handheld devices reduces barriers and access
to health technology, health insurance plans in North America
currently regard their use as experimental or investigational
with no pre-approval for reimbursement. Consumers’ ability to
self-perform continuous event recording without a physician’s
input is a paradigm shift with both opportunity due to the
ubiquitous presence and use of mobile devices around the world,
and challenge regarding appropriate and timely interpretation
of arrhythmic events. With time, validation and increased
acceptance, the above smartphone-enabled devices will likely
have a defined indication in outpatient heart rhythmmonitoring.
At a steady pace of miniaturization, long-term (months to
years), “in-body” implantable devices such as the USB memory
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FIGURE 1 | Contemporary options for cardiac monitoring. The
range of options for outpatient cardiac monitoring varies depending on
the intended study duration, the presence or absence of symptoms,
the need for continuous deployment (solid line with arrows) vs.
intermittent symptom-triggered monitoring, ability of the subject to
activate or initiate recording, likelihood of study completion specific to
device design, and lifestyle (e.g., hindrance to work and activities,
need for water resistance, ability to tolerate presence of device).
Dashed line with arrow indicates serial deployment of multiple patch
devices to achieve a study period of 30 days. ICD, implantable
cardioverter defibrillator. ICM, injectable cardiac monitor. ILR,
implantable loop recorder. PPM, pacemaker. *Manual contact and
triggering required for intermittent activation or operation. §Superseded
by SEEQ MCT.
stick-sized (62 × 19 × 8mm) Reveal R© XT (Medtronic, Inc.,
Minnesota, USA and Ireland, EU) have also undergone a
reduction in their footprint, with increased data storage capacity
and longer duration of study (up to 3 years for Reveal R© LINQ)
(Figure 2). Similar to non-invasive devices, the injectable cardiac
monitors (e.g., Reveal LINQ) are pushing the limits of minimally
invasive cardiac monitoring. The associated costs as well as the
suspect differential diagnoses will dictate the choice of non-
invasive and invasive modalities of rhythm monitoring, given
that the costs could differ by as much as 40-fold depending
on the device (ranging from US$104 for short-term Holter
monitor and US$275 for 30-day event recorder to US$4374
for implantable loop recorder for up to 2 years’ deployment;
prices may differ considerably depending on the institutions and
countries) (Zimetbaum and Goldman, 2010).
ECG Patch Devices
Adhesive AECG patch devices typically comprise a sensor
system, a microelectronic circuit with recorder and memory
storage, and an internal battery embedded in a relatively flexible
synthetic matrix, resin, or other material. They are usually
intended for medium-term use ranging from days to several
weeks, depending on the device (Figure 1). The self-contained
adherent unit typically has a low profile and can be affixed to the
body surface, usually over the left upper chest area, by means of
prefabricated adhesive material (Figure 2).
The main advantages of this kind of AECG system are
that they are easy to use, leadless, minimally intrusive to
daily activities, water-resistant, hygienic (i.e., single use only),
and incur no upfront cost to the clinic for the initial device
investment as compared to the wearable, reusable devices.
Because of easy application of the adhesive AECG patch to
skin and its unobtrusive maintenance-free nature, they have a
high study completion rate (Shinbane et al., 2013), implying a
high acceptance rate (long wear time) that should translate into
improved compliance compared to other short- to medium-term
devices such as the Holter monitor (Barrett et al., 2014).
Disadvantages of currently available adhesive AECG patch
devices include their high cumulative consumer costs (due to
non-reusability), dependence on the device company for raw
data retrieval, the company technician’s accurate collection and
reporting of raw data, and generation of a summary report. As
the ZIO XT system (iRhythm Technologies, Inc., San Francisco,
California, USA) requires that the user return the device in a
postage-paid envelope upon study completion, there is a lag time
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TABLE 1 | Comparison between two CE-marked, FDA-approved leadless, continuous electrocardiographic patch devices and the standard Holter
monitor.
ZIO® XT SEEQ™ (formerly NUVANT) MCT Holter monitor
Manufacturer iRhythm Technologies, Inc. Medtronic, Inc. (Corventis)* Variable
Data storage capacity 14 days 7.5 days; up to 30 days with deployment
of multiple units
24–72 h
Method of application Timed adhesive Timed adhesive Multiple detachable leads and adhesive pads
Number of ECG channel(s) 1 1 Multiple (typically, 3 and up to 12)
ECG resolution (bits) 10 16 Variable
ECG sample rate (Hz) 200 200 Variable
Detection range of heart rate (bpm) 0 to >300 25–250 Variable
Symptom trigger Yes Yes Yes
Water resistant Yes Yes No
Data transmission or upload
mechanism
Mail-in return of device for data
retrieval
Bluetooth between sensor and transmitter,
cellular transmission between transmitter
and server
In-house data download in clinic
Preliminary data processing,
management and reporting
Medicare certified independent
diagnostic testing facility,
certified technician
Medicare certified independent diagnostic
testing facility, certified technician
Clinic/Hospital-based technician
Weight (g) 34 50 Variable (average 100–150, min. 62)
Dimensions (mm) 123× 53 × 10.7 160× 60 × 15 100× 60 × 25 (average)
Associated components None Wireless transmitter, battery charger Leads, recorder, straps
Device cost§ Variable
(US$329)†
Variable
(US$718)¶
Variable(US$600 to $6000+)
For other multi-lead, multi-channel ambulatory telemetry systems, please refer to a review by Mittal et al. (You et al., 2012).
*Acquired by Medtronic plc. §Excluding clinic, technician and other fees. †Direct self-pay price. ¶Medicare negotiated price, qualified patient pays 20%.
from postage to data retrieval and processing by the company’s
ZIO ECG Utilization Service (ZEUS R©). The turnaround time
from device submission to availability of a summary report
could take days before the reader (usually, a cardiologist or
cardiac electrophysiologist) has access to review the data and
synthesize a diagnosis based on clinical grounds. The duration
of this processing period may not be of concern when the
ambulatory patient’s underlying condition is felt to be relatively
benign, without immediate hemodynamic consequence, or when
the device is used to assess arrhythmia burden or rate control
in response to suppression therapy. Some of these logistical
issues are circumvented by the Corventis NUVANT/Medtronic
SEEQ mobile cardiac telemetry (MCT) system (Engel et al.,
2012) through real-time data transmission to the company’s
data network. However, availability of data is still dependent on
time required for data processing by the company’s Monitoring
Center, though within a relatively shorter time frame compared
with the ZIO system. The inherent two-piece design of the
MCT system, consisting of the sensor (PiiX R©) and the separate
cellular data transmitter (zLink R©), may be less convenient for
some users. As an extension to the NUVANT MCT system, the
AVIVO R© mobile patient monitoring (MPM R©) system features
additional monitoring parameters including respiratory rate,
heart rate variability, activity, posture, and fluid status. These
available systems point to the need for innovative engineering
to harness the strengths of each technology in order to provide
a continuous wireless monitor that can not only record all
beats and therefore provide arrhythmia burden, but can also
wirelessly send important arrhythmic events in real time for
timely diagnosis and treatment.
The ZIO Patch and the NUVANT/SEEQ MCT systems
(Table 1) have been well accepted by study subjects, with 93.7%
of patients finding the former comfortable and 81% indicating
preference over the Holter monitor (Barrett et al., 2014).
Depending on the patient’s clinical presentation, the clinician’s
index of suspicion for a particular underlying arrhythmia or
conduction system disease, the timeframe allowed for ECG
data access, and taking into account the designs and logistical
aspects inherent in each device, the ordering clinician will have
to weigh these considerations when choosing the appropriate
device. The ZIO XT, NUVANT/SEEQ MCT, and AVIVO MPM
are approved by the U.S. Food and Drugs Administration
(FDA) and have received the CE Mark for use in the European
Union.
At the time of this writing, Medtronic plc. had acquired
Corventis, Inc. and was in the process of relaunching the
NUVANT MCT as the Medtronic SEEQ MCT for short- to
medium-term cardiac monitoring to complement their long-
term Reveal LINQ injectable monitor product line. Meanwhile,
iRhythm Technologies, Inc. has evolved their ZIO System into
a second-generation product, ZIO XT Patch, after successes
with their first-generation ZIO Patch. As the demand for user-
friendly adhesive AECG patch devices continues to increase, their
availability from Philips (Ackermans et al., 2012) (Eindhoven, the
Netherlands, EU) and other device manufacturers is expected in
the near future.
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FIGURE 2 | A selection of contemporary wireless mobile cardiac
monitoring devices. Two leading AECG adhesive patch devices on the
medical device market today are (A) second-generation ZIO® XT Patch by
iRhythm Technologies, Inc. and (B) SEEQ™ MCT patch device by Medtronic,
Inc. (cellular transmitter not shown). Featuring touch-activable electrodes
configured for the Apple iPhone or Androidbased systems are (C)
third-generation AliveCor® by AliveCor, Inc. and (D) ECG Check by Cardiac
Designs, LLC. As the first-in-class injectable cardiac monitor, (E) Reveal
LINQ™ (4.0× 7.2× 44.8mm; 2.4 g) by Medtronic, Inc. can record rhythm
data for up to 3 years.
Arrhythmias and Conduction System
Disorders Detection by AECG Systems and
Related Devices
Clinically relevant arrhythmias and conduction system
abnormalities that are detectable and reportable on AECG
studies include sinus tachycardia, bradycardia, AF, AFL,
supraventricular tachycardia, junctional rhythms/tachycardia,
atrial and supraventricular ectopy (premature complexes),
ventricular ectopy, ventricular tachycardia, pause (≥3 s), second-
degree atrioventricular block (type I Wenckebach, type II
Mobitz, high-grade AVB), and third-degree AVB (complete heart
block) (Table 2). Although QT intervals (e.g., drug-induced), QT
dispersion, and ST segment changes (e.g., myocardial ischemia)
are not routinely reported, data analysis and results reporting
could in theory incorporate these parameters for research
purposes or for clinical studies requiring such customization. In
particular, the limitations with ST segment monitoring reflect
the lack of specificity and the inherent bias if the endpoints
are gold-standard coronary angiography and intervention;
there is currently no “hard” endpoint data such as myocardial
infarction that is clinically relevant. Among clinically important
and common arrhythmias, ventricular tachyarrhythmia and
third-degree AVB are concerning for potential hemodynamic
and circulatory compromise, whereas AF is the most common
TABLE 2 | Overall organization of clinical and electrocardiographic data
from ambulatory cardiac monitoring.
I. General
a. Subject information
b. Enrollment period—days, hours
c. Analysis time—days, hours
d. Heart rate—maximum, minimum, range, average
e. Subject triggered events and diary entries
II. Arrhythmia type, conduction system abnormalities and specifics
a. Sinus tachycardia—number of episodes, duration, average rate, range
b. Bradycardia—number of episodes, duration, average rate, range
c. Pauses—number of episodes, duration, range
d. Junction rhythms or ectopy—burden (%), quantity
e. Atrioventricular block (type I, type II, 2:1, high-grade)—quantity
f. Complete heart block (third-degree)—quantity, duration
g. Atrial ectopy—burden (%), quantity
h. Atrial fibrillation—burden (%), range, rate, average
i. Atrial flutter—burden (%), range, rate, average
j. Supraventricular ectopy or tachycardia—burden (%), quantity
k. Wide complex tachycardia—quantity, rate
l. Ventricular ectopy (single, couplet, triplet, bigeminy, trigeminy)—type, burden (%),
quantity
m. Ventricular tachycardia (≥3 beats)—sustained (≥30 s) or non-sustained (<30 s),
burden (%)
III. Other relevant information
a. Subject triggered events relating to the above arrhythmias or conduction system
abnormalities
arrhythmia and strongly associates with stroke, increased risk of
cardiomyopathy, congestive heart failure and death (Wolf et al.,
1978; Krahn et al., 1995; Zipes, 1997; Chen et al., 2013; Reinier
et al., 2014).
Detection of paroxysmal AF is one of the main utilities
of AECG monitoring. AF detection algorithms configured in
ECG patch devices and data analysis software are usually
proprietary, but methods based on the Lorenz plot (or its
variants) of successive ventricular response (R–R) intervals
are used to distinguish AF from normal sinus rhythm
and/or other arrhythmias based on the premise of their
different dispersion characteristics. The ability of the device
to discriminate AF from atrial or other supraventricular
tachycardia requires rigorous testing during device engineering
and development, often using multiple test data sets [e.g.,
Massachusetts Institute of Technology-Beth Israel Hospital
(MIT-BIH) database, IMPROVE database, American Heart
Association (AHA) database)]. Test performance characteristics
are compared against benchmarks. In the real-world setting,
ECG patch devices (ZIO Patch) have very high concordance
(R = 0.96) in detection of AF compared with Holter
monitor (Rosenberg et al., 2013). When atrial or supraventricular
tachyarrhythmia occurs for ≥30 s, the episode is by default
recorded as an event by available AECG patch devices.
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The definition of AF may, however, depend on the clinical
study context. For example, some clinical studies only consider
AF as being present when the episode lasts≥30 s, a cut-off used to
demarcate freedom fromAF vs. AF recurrence in ablation studies
(Calkins et al., 2012). In the TRENDS study, increased AF burden
detected by pacemakers or defibrillators correlated with increased
thromboembolic events (ischemic stroke and transient ischemic
attack) (Glotzer et al., 2009), and more than 6min of rapid atrial
rate (or atrial tachyarrhythmia, a recognized precursor of AF,
with atrial rate >190 beats per minute) correlated with increased
risk of ischemic stroke or systemic embolism (Healey et al., 2012).
Using pacemakers programmed to log rapid atrial rate, atrial
tachyarrhythmia was also found to be an independent predictor
of death in the MOde Selection Trial (MOST) study (Glotzer
et al., 2003). The decision on whether to initiate anticoagulation
is clinical, depending on the patient’s risks (e.g., as gauged by
risk scores such as CHADS2, CHA2DS2-VASc, and HAS-BLED),
the duration and burden of AF, and other patient factors (Pisters
et al., 2010; You et al., 2012; Lip, 2013).
The prevalence estimate of atrial arrhythmias is primarily
dictated by the subject population under study. In the general
elderly population the prevalence of AF is in excess of 10%
(Heeringa et al., 2006), whereas an academic electrophysiology
practice, for example, could be referred patients (mean age 56.7
years ±20.2) with high pre-test probability of AF/AFL and an
actual prevalence of up to 20% (Eisenberg et al., 2014). The
lifetime risks for AF at age 40 years is 26% for men and 23%
for women based on risk calculations up to 95 years, and the
heightened risks remain similar at age 80 years (22.7 and 21.6%,
respectively) (Lloyd-Jones et al., 2004). Despite detailed reporting
of risk estimation and AF incidence rates in various populations
in Europe and North America (Krahn et al., 1995; Kannel et al.,
1998; Heeringa et al., 2006), it is recognized that the majority of
those large epidemiological studies were based on conventional
chart review, physical exam and 10-s ECGs for diagnosis of AF
(Wolf et al., 1978; Krahn et al., 1995; Kannel et al., 1998; Go et al.,
2001; Lloyd-Jones et al., 2004; Heeringa et al., 2006; Dewland
et al., 2013). Those case finding approaches are considered low-
yield (Mittal et al., 2011) and most probably underestimated the
true prevalence of AF. The ability to detect AF early is likely
influenced by a surprisingly low prevalence of symptoms in this
population. In a ZIO Patch study of 524 consecutive patients,
91 were identified with AF (Eisenberg et al., 2014). Only 46%
of patients experienced symptoms during a mean follow-up of 7
days. Furthermore, patients with permanent AF were even less
likely to report symptoms. Device deployment for an average
of 7 days likely accounted for the high diagnostic yield in this
patient population with a relatively high pre-test probability for
an arrhythmia compared to the general population (Eisenberg
et al., 2014).
The first diagnosis of AF often occurs in the unfortunate
setting of an acute ischemic stroke (Sherman et al., 1984). In
that patient population, it was clearly demonstrated that 24-h
ECG monitoring was profoundly insufficient for diagnosing AF
when compared to 72-h or 21-day monitoring (Schuchert et al.,
1999; Tayal et al., 2008). In a study of 82 consecutive patients 2–3
weeks after an acute ischemic stroke and in whom resting ECGs
showed normal sinus rhythm and no previously documented AF,
only 1 patient (1.2%) was found to have paroxysmal AF within
the first 24 h, 2 patients (2.4%) by 48 h and another 2 patients
(2.4%) at 72 h (Schuchert et al., 1999). In another study of 56
patients with cryptogenic TIA or stroke using 21-day mobile
telemetry monitoring, AF was diagnosed after a median of 7
days (Tayal et al., 2008). Moreover, 27 asymptomatic AF episodes
were detected in 13 patients, of which 23 (85%) were <30 s and
the remaining 4 (15%) were 4–24 h in duration (Tayal et al.,
2008). These studies highlight the challenges in diagnosing AF
with conventional monitoring even in relatively high arrhythmia
burden patients with paroxysms, and support the use of
prolonged ECG monitoring in most patients suspected to have
atrial arrhythmia(s) and/or neurologic symptoms suggestive
of impending or ongoing TIA or stroke that warrant close
monitoring and aggressive cardiovascular risk modification.
Using the 30-day event recorder or the Reveal XT implantable
cardiac monitor in two independent studies of cryptogenic stroke
(EMBRACE and CRYSTAL AF, respectively), their superiority
over standard 24-h ECG monitoring for diagnosis of AF lasting
30 s or longer was strongly affirmed [16.1% vs. 3.2% by 90
days in EMBRACE (Gladstone et al., 2014); 8.9% vs. 1.4% AF
diagnosed by 6 months and 12.4% vs. 2.0% by 12 months in
CRYSTAL AF (Sanna et al., 2014)], irrespective of study design,
patient demographics (e.g., mean age of 73 years in EMBRACE
and 61 years in CRYSTAL AF) and study endpoints. Overall,
this magnitude of increase in diagnostic yield is phenomenal.
In the ASSERT study on 2580 patients with mean age of 76–
77 years and in whom pacemaker implantation was indicated,
device monitoring of subclinical atrial tachyarrhythmias that
preceded the development of clinical AF was observed, shedding
new light on the clinical epidemiology and natural history
of the disease (Healey et al., 2012). These findings refute
subclinical atrial tachyarrhythmias in elderly patients as simply
benign.
Prolonged ECG monitoring studies have revealed that AF
remains vastly under-diagnosed, and that duration of cardiac
monitoring following acute ischemic stroke should be extended
beyond 24–48 h (Schuchert et al., 1999; Tayal et al., 2008; Elijovich
et al., 2009).With recent data affirming increased diagnostic yield
using AECG patch devices (ZIO Patch and Corventis NUVANT
MCT) compared to Holter monitors in patients with a relatively
high pre-test probability for an arrhythmia (Rosenberg et al.,
2013; Shinbane et al., 2013; Barrett et al., 2014), the epidemiology
of AF in the general population warrants a reappraisal.
The use of AECG in the detection and surveillance
of arrhythmias in patients with congenital heart disease is
expanding. Arrhythmias remain the most frequent clinical
sequelae for this patient population and are associated with
increased risks of thromboembolic events (Jensen et al., 2015)
and sudden cardiac death (Walsh, 2014). The prevalence of atrial
arrhythmias among adults with congenital heart disease over
a 22-year period is estimated at 15% (Bouchardy et al., 2009),
and the 20-year risk of developing atrial arrhythmias is ∼7%
at 20 years of age, increasing to 38% at 50 years (Bouchardy
et al., 2009). Severity of congenital heart disease also correlates
with development of arrhythmias, with moderate to severe forms
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having significantly higher risks; however, even those with mild
forms still remain at some risk (Walsh and Cecchin, 2007). Much
of our current understanding of arrhythmias and conduction
system disease in patients with congenital heart disease have
come from studies using 12-lead ECG and Holter monitor (Glatz
et al., 2010; Rodriguez et al., 2012; Czosek et al., 2013). Data on
longer duration recording are lacking.
In the pediatric population, the quantity of AECG patch
devices used remains low compared to that in adults.
Nevertheless, ZIO patch data on 3209 consecutive children
(mean age 12.5 years, range 1 month to 17 years) collected
between 2011 and 2013 in a national registry suggested a
relatively high diagnostic yield and short time to first detection
of arrhythmias in this population (Bolourchi and Batra, 2015).
Approximately 44–50% of the diagnoses were made beyond
48 h of cardiac monitoring, and the mean times to first detected
and first symptom-triggered arrhythmias were 2.7 ± 3.0 and
3.3 ± 3.3 days, respectively (Bolourchi and Batra, 2015). The
use of continuous ECG adhesive patch device requiring no
upkeep or maintenance for prolonged periods of at least
1 week seems prudent particularly in children and young
adults who have high pre-test probability for concerning
arrhythmia.
Clinical Performance and Evidence
Continuous, non-invasive AECG monitoring for up to 14 days
can be provided by each ZIO device, and up to 7.5 days for
each Medtronic SEEQ/Corventis NUVANT MCT (up to 30 days
when four sensors are used serially). Since the time to first
clinically relevant arrhythmia averages 5.8 ± 6.1 days (Shinbane
et al., 2013), these systems have high likelihood of clinching a
diagnosis where Holter monitors or event recorders (in case of
an asymptomatic arrhythmia) fall short. Indeed, ZIO Patch use
for ∼10.8 days resulted in detection of 81% more arrhythmias
compared with 24-h Holter monitoring (38 vs. 21 events, P <
0.001) in a study of 75 consecutive patients referred for AF
management at a tertiary medical center (Rosenberg et al., 2013).
In an analysis of 26,751 consecutive patients who wore the
ZIO Patch for 48 h vs. the entire duration of 7.6 ± 3.6 days,
the diagnostic yield significantly increased from 43.9 to 62.2%
for any arrhythmia, and from 4.4 to 9.7% for symptomatic
arrhythmia (Turakhia et al., 2013). Although there is a very
high concordance between the ZIO Patch and Holter monitor
in AF episode detection (R = 0.96) (Rosenberg et al., 2013),
Cheung and colleagues pointed out that within the first 24 h
of monitoring of any one of six arrhythmias (supraventricular
tachycardia, AF/AFL, pause >3 s, AVB, ventricular tachycardia,
or polymorphic ventricular tachycardia/fibrillation), the Holter
monitor detected about 17% more reportable events (on average,
61 events by Holter vs. 52 events by ZIO Patch, P = 0.013)
than the ZIO Patch (Cheung et al., 2014). This suggests that
while little difference existed in the accuracy and consistency of
AF detection between the ZIO Patch and Holter monitor, other
arrhythmias and conduction disorders may have potentially
been under-detected by the ZIO Patch, possibly owing to
its single-channel nature compared with the multi-channel
Holter monitor. The possibility of Holter monitor over-detecting
arrhythmias and conduction disorders can be ascertained upon
inspection of raw data. Differences in detection algorithms
could also be explanatory. It would be essential for future
studies to categorically identify the strengths and weaknesses
for each patch device in detecting each type of arrhythmia and
conduction system disease, to enable clinicians to choose the
most appropriate device.
The ZIO Patch has been demonstrated to be useful in
diagnosing and in guiding clinical management in different
settings. In a multicenter study of 174 patients presenting to
the emergency department with arrhythmia-related symptoms
(palpitations, syncope and/or dizziness) who were subsequently
discharged and enrolled into the study, the overall diagnostic
yield was 63.2% for arrhythmias (27.6% supraventricular
tachycardia ≥8 beats, 10.9% supraventricular tachycardia ≥4
but <8 beats, 8.1% ventricular tachycardia, 6.3% all AF, and
the remaining comprised of other arrhythmias and conduction
system disorders) (Schreiber et al., 2014). In another study of
patients undergoing management of AF, the use of ZIO Patch
led to a change in clinical management in over 28% of cases
(Rosenberg et al., 2013). Moreover, study subjects found the ZIO
patch more comfortable (Turakhia et al., 2013) and preferable
than the Holter monitor (93.7% vs. 51.7%, respectively) (Barrett
et al., 2014), and the total wear time of the NUVANT MCT
was high (completing 90% of days prescribed in 715 subjects)
(Shinbane et al., 2013), indicative of good compliance for both
patch devices (Barrett et al., 2014).
Clinical Implications
Adhesive AECG patch devices have recently been
demonstrated to be superior to Holter monitors in diagnosing
AF, largely due to a longer study period and higher study
completion rate owing to unobtrusive, user-friendly designs.
They will continue to be useful tools for quantifying arrhythmia
burden and surveillance of asymptomatic or symptomatic
arrhythmias and conduction system diseases such as intermittent
high-grade AVB or sick sinus syndrome. When used in large
cohort studies, these devices may be invaluable for recharting the
epidemiology of AF and other arrhythmias in both the general
and ambulatory patient populations. Supported by evidence of
practice-changing impact on clinical management (Rosenberg
et al., 2013), the benefits of adhesive AECG patch devices over
conventional short to medium term monitors should encourage
their broader yet judicious use, particularly for paroxysmal atrial
arrhythmias, documentation of burden of ventricular ectopy,
and during continual outpatient workup of cryptogenic stroke
when a suspect atrial arrhythmia evaded capture on inpatient
telemetry. The application of adhesive AECG patch devices in
children and in patients with congenital heart disease is growing,
though data on diagnostic yield is still lacking. With longer wear
period, the yield for detecting clinically significant arrhythmias
and symptom-provoking arrhythmias and conduction system
disease is expected to increase.
Available clinical society guidelines have yet to incorporate the
use of AECG patch devices. These devices are currently being
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prescribed for similar indications as for Holter monitor, however,
differences in device characteristics, study duration, diagnostic
yield and study completion rate call for special attention in
guideline development and revision. In the near future, the
Heart Rhythm Society is expected to set out recommendations
to improve device use appropriateness and aid management
decisions.
Vision of the Future
Several years ago, Google (Google Health), Microsoft (Microsoft
HealthVault), Dossia (Dossia, an open-source software supported
by a large number of health industry stakeholders) and others
initiated efforts to democratize digital health record stewardship
using cloud-based platforms to enable easy access via the internet
(Weitzman et al., 2009). Successes have thus far been hampered
by privacy concerns and by the conventional, patriarchal model
and proprietary silo-building inherent in established health care
organizations. Internet-accessible PCHR have been championed
by some, but many issues ranging from user’s technological
literacy to confidentiality and privacy risks have been voiced and
remain areas of vigorous debate and interest (Weitzman et al.,
2009). Moreover, there exists controversies over information
access and appropriate usage by keyholders and other parties,
data disclosure and privacy (Haas et al., 2011).
With emergence of AECG patch devices, smartphone-
enabled wireless ECG and cardiac monitors over the past few
years, the ease with which voluminous health data can be
generated has accelerated. Revisiting the open-access PCHR
models may lead to unfettered access and empower individuals
to self-manage and potentially self-diagnose under physicians
guidance. Notwithstanding the concerns of a loss of control
in patient management, this modality of health information
management along with well-planned, scalable digital health
infrastructure could enable physicians to increase the volume of
patients seen, reduce the time to diagnosis, improve efficiency
and efficacy of disease management, and reduce unnecessary
clinic visits and hospital admissions. At the forefront of
digital health evolution, the above described miniaturized
technologies coupled with PCHR are poised to improve patient
adherence, and the detection, characterization and monitoring of
cardiac arrhythmias—readily digitalizedmarkers and phenotypes
of cardiovascular disease—that are already making inroads
into clinical diagnosis, patient management and healthcare
transformation.
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